Dr. Marinos C. Dalakas, MD

Dr. Dalakas practices at Jefferson University Physicians in Philadelphia, Pennsylvania.

Dr. Dalakas' NPI, 1275739906, was assigned on June 21, 2007. Dr. Dalakas holds Pennsylvania license MD431100.

Dr. Dalakas' primary practice is Jefferson University Physicians, at 909 Walnut St, Philadelphia, PA 19107 in Philadelphia County. The practice phone is (215) 955-0000.

Dr. Dalakas' primary practice is Jefferson University Physicians in Philadelphia, Pennsylvania. Dr. Dalakas is also affiliated with Thomas Jefferson University Hospital. The medical group on file is Jefferson University Physicians. Dmand AI also links Dr. Dalakas to 1 more group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Dalakas practices, 2 sites in all. Vendor and product names are available with a free account.

Neurology is Dr. Dalakas' primary specialty in the NPI Registry, under taxonomy code 2084N0400X. Dr. Dalakas is licensed in Pennsylvania.

CMS data shows 228 Medicare services from Dr. Dalakas across 3 procedure codes in 2024, all of them office visits, for 138 Medicare patients. Medicare paid $27,289 for them.

CMS counts 138 Medicare patients who saw Dr. Dalakas in 2024. The largest group is 65 to 74, with 58 patients. 75% of them have high cholesterol, and 72% have high blood pressure. 11% are also on Medicaid. Their average risk score is 1.57, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Dalakas' median patient age at 64, with 49% women.

In 2024, Dr. Dalakas wrote 326 Medicare Part D claims for 30 patients. 9% of them were for generic drugs. CMS names the drug for 284 of them, across 6 drugs with 11 or more claims each, at $4,169,328 in total drug cost. In 2023, CMS named 322 claims across 10 drugs.

Dr. Dalakas accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Dalakas as offering telehealth.

Dmand AI links 164 papers to Dr. Dalakas, published from 2002 to 2025. 2022 was the busiest year, with 10. The most frequent topics are Autoantibodies, Immunoglobulins, Intravenous and Myositis, Inclusion Body. Dr. Dalakas has published most often in Neurol Neuroimmunol Neuroinflamm. Dr. Dalakas' most frequent co-authors are Norman Latov, MD, Goran Rakocevic, MD and Peter Daniel Donofrio, MD.

Dmand AI links Dr. Dalakas to 7 clinical trials, 2 of them phase 2 studies. Conditions studied include Myasthenia Gravis, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating and Neuromuscular Junction Diseases. Baxalta now part of Shire sponsors the most, 2. Open Payments lists research payments to Dr. Dalakas that name 2 trials.

CMS Open Payments shows 86 general payments to Dr. Dalakas from 17 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 65% of the total. Sanofi and Genzyme US Companies paid the most, $36,210. It also lists 32 research payments totaling $27,200 from 2019 to 2025, naming 2 clinical trials.